Member Info for Rockefellow

Will get very tight if start to close

Celea is expected to have a multibillion dollar valuation.Possible Nasdaq float in 12 to 18months.stake will be clearly diluted in the current funding.Seaport worth $275m.,,.can sell some 180 days after list.cash going down.

ADRs barely trade so listing an unnecessary expense.Er..are Tang 5pc Briarwood 5pc not US investors.

Rubbish.Adjustments will already have been made.US investors can still buy/hold stock.

You are wasting your time with detailed letters to management.Daphne is the Queen of hype.Pure has had many hyped up disasters over the years if you look back.Her original backers will have been the source of endless selling since she left.These guys were well positioned to back Seaport in the IPO.The $100m tender offer allowed her to sell $8m stock.She has been paid around $20m over the years.Look how Seaport has crashed after the hype.Well done for raising $500m however.A new generation of shareholders like Tang and Briarwood have taken the place of Daphne’s crowd.So Robert L will be lazer focused at moving Puretech forward.Lowball PE approaches will be a waste of time.

Briarwood own 15pc Oxford Biomedica

That’s the problem.Seaport over hyped.below offer price

1.7m Fri 1m today it not low volume.ADR holders are having to sell before they delist.adrs are 10 for 1.thats the problem

Maybe 20pc chance.

Re Cobenfy.Sales are currently running at $56m per quarter.I think will be luck to hit $500m at peak.So BMS paid a stupid price for Karuna.remaining royalties might be worth $50m npv so isn’t going to move the needle.Great that Daphne was still able to use the $14bn benchmark to build a war chest for Seaport.

Roadshow underway..

Https://puretechhealth.com/wp-content/uploads/PRTCCorpPresentation.pdf

Seaport now has plenty of cash..and a listing.No data news until q1 next year.

OFEV now has generic competition.So sales will be down around 90pc.

Generic Pirfenidone costs around $5000 a year..not a month.If efficacy is at most 50pc better..and you are going to die anyway what price is realistic.the glory days of $4bn pa are long gone.

The original launch cost of Pirfenidone was around $94000 pa.the Generic version is now around a few thousand.

Https://www.businesswire.com/news/home/20260430960640/en/Seaport-Therapeutics-Announces-Pricing-of-Upsized-Initial-Public-Offering?feedref=JjAwJuNHiystnCoBq_hl-W8j9Oi60kFTomUxRDB8jhBsNpnJw7dvSfTyni2BOVIOrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3nDlC87j5HoE75BMeA8LaVacVjEfZIyqgxRRsuxHCTK2w%3D%3D&utm_source=dlvr.it&utm_medium=twitter

Puretech was able to strike a $500m deal for their 3pc Karuna royalty after 3 successful registrational trials.In reality that was $100m up front plus $30m so far.

Where is UBS?I did ask in the presentation.

Forget Cobenfy..yes.Im sure expectations will be reset tomorrow.